Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNT-01 in Idiopathic Triglyceride Deposit Cardiomyovasculopathy
NCT02502578Phase 2Completed
- Sponsor
- The University of Osaka
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial of tricaprin in idiopathic triglyceride deposit cardiomyovasculopathy (I-TGCV), sponsored by The University of Osaka. Primary endpoints: Adverse Events at 29 days and 12-lead Electrocardiogram at 29 days. Started Sep 2015; status: completed.
02
Drugs
tricaprin
03
Conditions
idiopathic triglyceride deposit cardiomyovasculopathy (I-TGCV)
Beyond the preview
Go deeper on NCT02502578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502578.